| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2023-02-21 17:15:13 UTC |
|---|
| HMDB ID | HMDB0000840 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Salicyluric acid |
|---|
| Description | Salicyluric acid is an aryl glycine conjugate formed by the body to eliminate excess salicylates, including aspirin. Aspirin is rapidly hydrolysed to salicylic acid which is further metabolized to various compounds, including salicyluric acid (SU) as well as various acyl and phenolic glucuronides, and hydroxylated metabolites. SU is the major metabolite of SA excreted in urine and it is present in the urine of people who have not taken salicylate drugs, although it has no anti-inflammatory effects in humans or in animals. More salicyluric acid (SU) is excreted in the urine of vegetarians than in non-vegetarians, primarily because fruits and vegetables are important sources of dietary salicylates. However, significantly less (10-15X) SU is excreted by vegetarians than individuals taking low-dose aspirin (PMID: 12944546 ). The induction of the salicyluric acid formation is one of the saturable pathways of salicylate elimination. The formation of the methyl ester of salicyluric acid is observed during the quantitation of salicyluric acid and other salicylate metabolites in urine by high-pressure liquid chromatography. This methyl ester formation causes artificially low values for salicyluric acid and high values for salicylic acid. (PMID: 6101164 , 6857178 ). Salicyluric acid has been found to be a microbial metabolite. |
|---|
| Structure | OC(=O)CNC(=O)C1=C(O)C=CC=C1 InChI=1S/C9H9NO4/c11-7-4-2-1-3-6(7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13) |
|---|
| Synonyms | | Value | Source |
|---|
| N-(2-Hydroxybenzoyl)-glycine | ChEBI | | N-Salicyloylglycine | ChEBI | | O-Hydroxyhippuric acid | ChEBI | | Salicyloylglycine | ChEBI | | Salicylurate | ChEBI | | O-Hydroxyhippate | Generator | | O-Hydroxyhippic acid | Generator | | Salicylate | Generator | | Salicylic acid | Generator | | ((2-Hydroxybenzoyl)amino)acetic acid | HMDB | | (2-Hydroxybenzoyl)glycine | HMDB | | 2-Hydroxybenzoylaminoacetate | HMDB | | 2-Hydroxybenzoylaminoacetic acid | HMDB | | 2-Hydroxybenzoylglycine | HMDB | | 2-Hydroxyhippurate | HMDB | | 2-Hydroxyhippuric acid | HMDB | | N-O-Hydroxybenzoylglycine | HMDB | | O-Hydroxy-hippurate | HMDB | | O-Hydroxy-hippuric acid | HMDB | | O-Hydroxyhippurate | HMDB | | Ortho-hydroxyhippurate | HMDB | | Ortho-hydroxyhippuric acid | HMDB | | Salicylglycine | HMDB | | [(2-Hydroxybenzoyl)amino]acetate | HMDB | | [(2-Hydroxybenzoyl)amino]acetic acid | HMDB | | Salicylurate, monosodium salt | HMDB | | N-(O-Hydroxybenzoyl)glycine | HMDB | | 2-[(2-Hydroxybenzoyl)amino]acetic acid | HMDB | | 2'-Hydroxyhippuric acid | HMDB |
|
|---|
| Chemical Formula | C9H9NO4 |
|---|
| Average Molecular Weight | 195.1721 |
|---|
| Monoisotopic Molecular Weight | 195.053157781 |
|---|
| IUPAC Name | 2-[(2-hydroxyphenyl)formamido]acetic acid |
|---|
| Traditional Name | salicyluric acid |
|---|
| CAS Registry Number | 487-54-7 |
|---|
| SMILES | OC(=O)CNC(=O)C1=C(O)C=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C9H9NO4/c11-7-4-2-1-3-6(7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13) |
|---|
| InChI Key | ONJSZLXSECQROL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as hippuric acids. Hippuric acids are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzoic acids and derivatives |
|---|
| Direct Parent | Hippuric acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Hippuric acid
- N-acyl-alpha amino acid or derivatives
- N-acyl-alpha-amino acid
- Alpha-amino acid or derivatives
- Salicylic acid or derivatives
- Salicylamide
- Benzoyl
- 1-hydroxy-4-unsubstituted benzenoid
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Vinylogous acid
- Carboxamide group
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Carbonyl group
- Organic oxygen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 168 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 0.95 | HANSCH,C ET AL. (1995) |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.21 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.0728 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.87 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 108.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1205.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 294.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 93.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 178.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 81.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 295.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 364.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 250.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 684.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 307.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1007.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 227.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 274.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 537.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 208.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 198.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Salicyluric acid,1TMS,isomer #1 | C[Si](C)(C)OC(=O)CNC(=O)C1=CC=CC=C1O | 1958.6 | Semi standard non polar | 33892256 | | Salicyluric acid,1TMS,isomer #2 | C[Si](C)(C)OC1=CC=CC=C1C(=O)NCC(=O)O | 1993.1 | Semi standard non polar | 33892256 | | Salicyluric acid,1TMS,isomer #3 | C[Si](C)(C)N(CC(=O)O)C(=O)C1=CC=CC=C1O | 1933.4 | Semi standard non polar | 33892256 | | Salicyluric acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)CNC(=O)C1=CC=CC=C1O[Si](C)(C)C | 2085.3 | Semi standard non polar | 33892256 | | Salicyluric acid,2TMS,isomer #2 | C[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O)[Si](C)(C)C | 1926.0 | Semi standard non polar | 33892256 | | Salicyluric acid,2TMS,isomer #3 | C[Si](C)(C)OC1=CC=CC=C1C(=O)N(CC(=O)O)[Si](C)(C)C | 2002.8 | Semi standard non polar | 33892256 | | Salicyluric acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C)[Si](C)(C)C | 2016.3 | Semi standard non polar | 33892256 | | Salicyluric acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C)[Si](C)(C)C | 2007.6 | Standard non polar | 33892256 | | Salicyluric acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C)[Si](C)(C)C | 2151.2 | Standard polar | 33892256 | | Salicyluric acid,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CNC(=O)C1=CC=CC=C1O | 2204.0 | Semi standard non polar | 33892256 | | Salicyluric acid,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC=CC=C1C(=O)NCC(=O)O | 2245.1 | Semi standard non polar | 33892256 | | Salicyluric acid,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(CC(=O)O)C(=O)C1=CC=CC=C1O | 2175.6 | Semi standard non polar | 33892256 | | Salicyluric acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CNC(=O)C1=CC=CC=C1O[Si](C)(C)C(C)(C)C | 2547.3 | Semi standard non polar | 33892256 | | Salicyluric acid,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O)[Si](C)(C)C(C)(C)C | 2417.7 | Semi standard non polar | 33892256 | | Salicyluric acid,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC=CC=C1C(=O)N(CC(=O)O)[Si](C)(C)C(C)(C)C | 2489.8 | Semi standard non polar | 33892256 | | Salicyluric acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2685.1 | Semi standard non polar | 33892256 | | Salicyluric acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2615.7 | Standard non polar | 33892256 | | Salicyluric acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CN(C(=O)C1=CC=CC=C1O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2530.1 | Standard polar | 33892256 |
|
|---|
| General References | - Buskin JN, Upton RA, Williams RL: Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine. Clin Chem. 1982 May;28(5):1200-3. [PubMed:7074905 ]
- Cham BE, Bochner F, Imhoff DM, Johns D, Rowland M: Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in urine. Clin Chem. 1980 Jan;26(1):111-4. [PubMed:7356541 ]
- Sakurai M, Ohsako M, Nagano M, Nakamura C, Tsuzuki O, Ichikawa M, Matsumoto Y: [Effect of human serum albumin on transport of drugs through human erythrocyte membranes]. Yakugaku Zasshi. 1996 Aug;116(8):630-8. [PubMed:8831264 ]
- Pirker R, Huck CW, Popp M, Bonn GK: Simultaneous determination of gentisic, salicyluric and salicylic acid in human plasma using solid-phase extraction, liquid chromatography and electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):257-64. [PubMed:15315774 ]
- Lares-Asseff I, Juarez-Olguin H, Flores-Perez J, Guille-Perez A, Vargas A: Pharmacokinetics and metabolic rates of acetyl salicylic acid and its metabolites in an Otomi ethnic group of Mexico. Biol Pharm Bull. 2004 May;27(5):706-9. [PubMed:15133250 ]
- Farid NA, Born GS, Kessler WV, Shaw SM, Lange WE: Improved colorimetric determination of salicylic acid and its metabolites in urine. Clin Chem. 1975 Jul;21(8):1167-8. [PubMed:1137922 ]
- Kershaw RA, Mays DC, Bianchine JR, Gerber N: Disposition of aspirin and its metabolites in the semen of man. J Clin Pharmacol. 1987 Apr;27(4):304-9. [PubMed:3680588 ]
- Lawrence JR, Peter R, Baxter GJ, Robson J, Graham AB, Paterson JR: Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J Clin Pathol. 2003 Sep;56(9):651-3. [PubMed:12944546 ]
- Arancibia JA, Olivieri AC, Escandar GM: First- and second-order multivariate calibration applied to biological samples: determination of anti-inflammatories in serum and urine. Anal Bioanal Chem. 2002 Oct;374(3):451-9. Epub 2002 Sep 11. [PubMed:12373394 ]
- Baxter GJ, Lawrence JR, Graham AB, Wiles D, Paterson JR: Identification and determination of salicylic acid and salicyluric acid in urine of people not taking salicylate drugs. Ann Clin Biochem. 2002 Jan;39(Pt 1):50-5. [PubMed:11853189 ]
- Day RO, Dromgoole SH, Furst DE, Hignite C, Paulus HE: Formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high-pressure liquid chromatography. J Pharm Sci. 1981 Sep;70(9):1090-2. [PubMed:6101164 ]
- Olsson B: Decreasing serum salicylate concentrations during long-term administration of acetylsalicylic acid in healthy volunteers. Discussion of possible clinical implications. Scand J Rheumatol. 1983;12(2):81-4. [PubMed:6857178 ]
|
|---|